Inhibrx Biosciences, Inc. 8-K

What Happened
On June 15, 2026, Inhibrx Biosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its Biologics License Application (BLA) for ozekibart (INBRX-109) to treat patients with unresectable or metastatic conventional chondrosarcoma. The FDA has not identified any filing review issues at this time and assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027.

Key Details

• Company: Inhibrx Biosciences, Inc. (INBX) — announcement made via Form 8-K dated June 15, 2026.
• Drug: Ozekibart (INBRX-109), for unresectable or metastatic conventional chondrosarcoma.
• Regulatory status: BLA accepted for filing by FDA; no filing review issues identified.
• Timeline: FDA PDUFA goal date set for April 14, 2027.

Why It Matters
BLA acceptance starts the formal FDA review process and sets a target decision date (PDUFA). For investors, this marks a key regulatory milestone: a successful review could lead to U.S. approval and commercial opportunity for ozekibart in a rare cancer indication. The announcement itself does not guarantee approval or revenue and contains no new financial results, but it is a material development in the company’s drug-development timeline.